Phase 2 N=27 Prescription Opioid Effects in Abusers Versus Non-Abusers
Opioid-Related Disorders · Substance-Related Disorders
Primary: Breakpoint — 25; 400; 1400; 850 Mouse Clicks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 2 N=16 A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
Opioid Use Disorder
Primary: Positive Subjective Drug Effects (i.e., Drug "Liking"). — 52.1; 57.5; 71.8; 71.5 units on a scale — p=.0001
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
Phase 2 N=49 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Opioid Abuse
Primary: Drug Liking at .5 Hours — 66.0; 74.7; 47.7; 40.9 score on a scale
Phase 4 N=60 Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
Abuse Potential
Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 54.30; 90.85; 72.53; 76.05 Score on a 100 mm scale — p=<0.0001
Phase 4 N=63 Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
Abuse Potential
Primary: Drug Liking Visual Analog Scale (VAS) — 56.4; 84.9; 59.6; 64.6 score on a scale
Phase 2 N=30 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Opioid Abuse
Primary: Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min) — 11.7; 14.7 score on a scale
Phase 2 N=17 Medication Development for Opioid and Alcohol Abuse
Opioid-use Disorder · Alcohol Use Disorder
Primary: Peak Positive Subjective Responses to Placebo. — 3.3; 2.3 units on a scale
Phase 2 N=28 Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Opioid Abuse · Opioid Dependence
Primary: Drug Self-administration Breakpoint — 347; 363; 1472; 43 Clicks on a computer mouse
N/A N=49 Consensus-based Algorithms to Address Opioid Misuse Behaviors Among Individuals Prescribed Long-term Opioid Therapy
Opioid Misuse · Chronic Pain
Primary: Feasibility of Algorithms — 7; 13 Participants
Phase 3 N=665 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
Opioid Dependence · Opioid Related Disorders
Primary: Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From…
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
N/A N=437 OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Opioid-use Disorder
Primary: Treatment Success Rate — 70; 67 Participants — p=0.7326
Phase 2 N=10 An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
Opioid-use Disorder
Primary: Sublocade Induction — 10 Participants
N/A N=200 Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes
Opioid-use Disorder · Medication Assisted Treatment · Chronic Pain
Primary: Retention on Buprenorphine Treatment According to TimeLine Follow-Back - 3-months — 81.1; 75.4 days
N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
Phase 1 N=27 Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
Opioid Abuse · Opioid Dependence · Opioid-Related Disorders
Primary: Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale — -13.81; -9.67 units on a scale
Phase 2 N=103 Medications Development for Drug Abuse Disorders
Opioid Related Disorders · Opioid Dependence · Opioid Addiction
Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…
Phase 1 N=75 A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
Healthy
Primary: Drug Liking: Peak Effect (Emax) — 51.6; 70.1; 85.5; 59.3 mm — p=<0.0001
Phase 1 N=80 Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Nondependent Opioid Abuse, Episodic
Primary: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours — 88.3; 100.3; 124.7 hrs*mm — p=<0.0001
Phase 2 N=32 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Opioid Abuse
Primary: Subjective Ratings of "Good" Drug Effect — 37; 35; 35 units on a scale
Phase 1 N=11 The Behavioral Effects of Opioids and Alcohol
Opioid Use · Alcohol Drinking
Primary: Peak Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 12.9; 47.1; 49.9; 54.8 score on a scale
N/A N=76 Evaluation of a Computerized Opioid Overdose Prevention Program
Computer + Fluency · Computer Only · Treatment as Usual
Primary: Knowledge Gain — 30.6; 30.5; 27.56; 40.7 units on a scale
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Phase 1 N=12 A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route
Pain · Nausea · Vomiting
Primary: Subjective Effects: Maximum Effect (Emax) and Minimum Effect (Emin) of High Visual Analog Scale (VAS) in Dose Selection Phase — 85.0; 42.0; 75.5; 94.0 units on a scale